Investigation of the Molecular Mechanism of Coagulopathy in Severe and Critical Patients With COVID-19

新冠肺炎重症和危重症患者凝血功能障碍分子机制的研究

阅读:2

Abstract

Coagulopathy is a frequently reported finding in the pathology of coronavirus disease 2019 (COVID-19); however, the molecular mechanism, the involved coagulation factors, and the role of regulatory proteins in homeostasis are not fully investigated. We explored the dynamic changes of nine coagulation tests in patients and controls to propose a molecular mechanism for COVID-19-associated coagulopathy. Coagulation tests including prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen (FIB), lupus anticoagulant (LAC), proteins C and S, antithrombin III (ATIII), D-dimer, and fibrin degradation products (FDPs) were performed on plasma collected from 105 individuals (35 critical patients, 35 severe patients, and 35 healthy controls). There was a statically significant difference when the results of the critical (CRT) and/or severe (SVR) group for the following tests were compared to the control (CRL) group: PT(CRT) (15.014) and PT(SVR) (13.846) (PT(CRL) = 13.383, p < 0.001), PTT(CRT) (42.923) and PTT(SVR) (37.8) (PTT(CRL) = 36.494, p < 0.001), LAC(CRT) (49.414) and LAC(SVR) (47.046) (LAC(CRL) = 40.763, p < 0.001), FIB(CRT) (537.66) and FIB(SVR) (480.29) (FIB(CRL) = 283.57, p < 0.001), ProC(CRT) (85.57%) and ProC(SVR) (99.34%) (ProC(CRL) = 94.31%, p = 0.04), ProS(CRT) (62.91%) and ProS(SVR) (65.06%) (ProS(CRL) = 75.03%, p < 0.001), D-dimer (p < 0.0001, χ(2) = 34.812), and FDP (p < 0.002, χ(2) = 15.205). No significant association was found in the ATIII results in groups (ATIII(CRT) = 95.71% and ATIII(SVR) = 99.63%; ATIII(CRL) = 98.74%, p = 0.321). D-dimer, FIB, PT, PTT, LAC, protein S, FDP, and protein C (ordered according to p-values) have significance in the prognosis of patients. Disruptions in homeostasis in protein C (and S), VIII/VIIIa and V/Va axes, probably play a role in COVID-19-associated coagulopathy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。